http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Chien-hua Fu ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Fundamental Study on Electrostatic Atomization of Biofuel/Water Emulsion
( Chien-hua Fu ),( Osamu Imamura ),( Kazuhiro Akihama ),( Hiroshi Yamasaki ) 한국액체미립화학회 2017 한국액체미립화학회 학술강연회 논문집 Vol.2017 No.-
This paper reports the experimental investigation of electrostatic atomization of BDF/water emulsion. Biofuel, such as Bio Diesel Fuel (BDF), is expected as the alternate fuel because of its carbon-neutral characteristics. In the process of making the biofuels, biofuels include water and the separation energy cost is relatively high. From this viewpoint, it is expected that the water in the biofuel is utilized in a positive manner. Biofuel and water mixture usually have large electric conductivity in comparison with hydrocarbons and it is possible to control of atomization using the electrostatic energy. In addition, if the droplets and spray are charged, the spray shape and flame pattern could be controlled to enhance the combustion and to reduce the heat loss to the wall. From this background, the paper mainly is focused on the electrostatic atomization of the BDF/water mixture. For the comparison, n-hexadecane is used as a reference fuel. The mixture fraction of water is the parameter of the fuel. To keep the stable mixture, surface active agent was added in the tested fuels. The viscosity of some tested fuel was high and the characteristics of non-Newtonian viscosity were researched prior to atomization experiments. The thin capillary to inject the fuel and wire netting over the capillary are used as electrodes and direct current voltages are applied to the electrodes. The fuel is pushed by the pressurized nitrogen and injected to the air through the capillary. As the results, fraction of water affects the onset of mode change, such as dripping, spindle, cone-jet etc. Droplets diameters and droplets velocity were measured from the video images and the electric charge distribution was discussed to understand the electrostatic atomization.
-
( Ming-lung Yu ),( Chao-hung Hung ),( Yi-hsiang Huang ),( Cheng-yuan Peng ),( Chun-yen Lin ),( Pin-nan Cheng ),( Rong-nan Chien ),( Shih-jer Hsu ),( Chen-hua Liu ),( Jee-fu Huang ),( Chung-feng Huang 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: The current study aims to elucidate the treatment efficacy (defined as undetectable HCV RNA throughout 12 weeks of post-treatment follow-up, SVR12) and safety DCV/ASV plus ribavirin for 12 weeks in HCV-1b patients without NS5A RAS. Methods: This is a single-arm, open-label phase 2 study. Seventy directly acting antivirals (DAA)-naïve HCV-1b patients without L31/Y93 RAS are planned to receive daclatasvir (60 mg/ day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/day) for 12 weeks. After treatment they were followed up for 12 weeks. Results: As of 31 Oct 2017, 58 eligible patients are allocated to treatment, with a mean age of 59.3 years and female predominance (67.2%, 39/58). The mean HCV RNA was 5.87+0.77 log10 IU/mL; 23 patients (39.7 %) had significant hepatic fibrosis (>F2). In the modified intention-to-treat analysis, the rate of undetectable HCV at week 1, week 2, week 4, week 8 and endof- treatment was 25 % (14/56), 84.8 % (39/46), 100 % (46/46), 100 % (38/38) and 100 % (27/27), respectively. Undetectable HCV RNA were observed in all of the patients with HCV RNA assessable 4 weeks (SVR4, 18/18) and 12 weeks (SVR12, 12/12) post treatment. None of the 18 patients who completed the 12-week treatment experienced relapse during post-treatment follow-up. The most common adverse event was fatigue (78.3 %), followed by pruritus (65.2 %) and dizziness (52.2 %), of which were considered as ribavirin related. None of the participating subjects withdrew treatment or follow-up throughout the trial peroid. Three serious adverse events were reported which included urosepsis, appendicitis and left ureteral stone. All were unrelated to the investigating drugs. Conclusions: 12 weeks of DCV/ASV plus ribavirin was highly effective and safe in HCV-1b patients without NS5A RAS in the interim analysis. The satisfactory results would be anticipated in the full patient set.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
